Abstract
Photodynamic therapy (PDT) is alive and well in the United States. Although many contemporary research scientists and clinicians still consider PDT a niche therapy, with little appeal in mainstream medicine, PDT is an approved treatment in oncology for airway malignancies, Barrett’s esophagus with high-grade dysplasia, and nonmelanoma skin cancer. In addition, PDT has been used in the laboratory and in some investigational clinical settings for high-grade gliomas, oral and laryngeal lesions, inoperable cholangiocarcinomas, and lung-sparing surgery for malignant pleural mesothelioma. To crystallize the wealth of preclinical and clinical experiences with PDT in oncology and to explore potential emerging indications and refinements in technique, various colleagues from both sides of the Atlantic joined me at the inaugural International Photodynamic Medicine Symposium at The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute in Columbus, Ohio, on May 11 and 12, 2012. This collaborative think tank included clinicians in thoracic surgery, gastroenterology, dermatology, and hepatology, and immunologists, physicists, biochemists, and photobiologists. Speakers
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the National Comprehensive Cancer Network
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
